House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Rheumatology

Behçet’s syndrome — 2025 update

EULAR · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

EULAR’s updated Behçet syndrome recommendations organise treatment around affected organs, prevention of lasting damage, and patient-centred multidisciplinary care. The reproduced recommendations cover mucocutaneous, joint, ocular, vascular, gastrointestinal and parenchymal neurological disease. They support organ-specific treatment choices but do not supply the full journal rationale or detailed prescribing schedules.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Assess disease extent and agree treatment goals

  • Evaluate organ involvement throughout the course of Behçet syndrome and investigate appropriate alternative diagnoses. Relapsing disease can threaten organs or life even though manifestations may lessen over time. [1]
  • Set prevention of irreversible organ damage and improvement in health-related quality of life as treatment goals. Individualise the plan to age, sex, organ involvement and severity, disease duration, and patient preferences. [1]
  • Use multidisciplinary care, patient education and shared decisions to support adherence and lifestyle changes. The recommendations make these components part of optimal care alongside medication. [1]

Treat mucocutaneous and joint disease

  • Use colchicine first for recurrent mucocutaneous lesions. If it is ineffective or not tolerated, consider apremilast or a tumour necrosis factor inhibitor. [1]
  • Topical treatments, including topical glucocorticoids, can be used for oral and genital ulcers. Avoid chronic systemic glucocorticoid treatment for these ulcers. [1]
  • Use colchicine as first-line treatment for acute arthritis. Consider immunosuppressive treatment when arthritis becomes recurrent or chronic. [1]

Protect vision with immunosuppressive treatment

  • Give immunosuppressive treatment to all patients with Behçet uveitis, aiming to induce and maintain both clinical and angiographic remission. [1]
  • For sight-threatening posterior segment inflammation, use a monoclonal anti-TNF antibody; infliximab combined with other immunosuppressives is preferred in this recommendation. Do not give glucocorticoids as the sole treatment. [1]

Treat arterial aneurysms promptly

  • For pulmonary or peripheral artery aneurysms, the recommendation favours high-dose glucocorticoids with infliximab; cyclophosphamide is an alternative. [1]
  • Taper glucocorticoids slowly and continue maintenance immunosuppression, preferably with a monoclonal anti-TNF antibody. [1]
  • Initiate medical treatment promptly and do not delay necessary vascular procedures thereafter. For pulmonary artery aneurysms with high major-bleeding risk, prefer embolisation over open surgery. [1]

Balance thrombosis treatment against bleeding risk

  • For acute deep-vein thrombosis, including cerebral venous sinus thrombosis, consider glucocorticoids and immunosuppressives, preferably monoclonal anti-TNF antibodies. Continue immunosuppressive treatment for maintenance. [1]
  • Anticoagulation may be added only after confirming low bleeding risk and excluding coexistent pulmonary artery aneurysms. This is a conditional addition, not an unrestricted anticoagulation recommendation. [1]
  • Give prompt consideration to surgical intervention when cerebral venous sinus thrombosis causes intracranial hypertension that threatens vision. [1]

Manage gastrointestinal and parenchymal neurological disease

  • Base diagnosis, severity assessment and treatment planning for gastrointestinal involvement on endoscopy. [1]
  • Use 5-aminosalicylic acid (5-ASA) or azathioprine for gastrointestinal disease, with or without glucocorticoids. Consider a monoclonal anti-TNF antibody for severe or refractory disease. [1]
  • For active parenchymal nervous system disease, initiate high-dose glucocorticoids and immunosuppression, preferably infliximab. Taper glucocorticoids slowly and maintain immunosuppressive treatment. [1]

Limitations and use

  • These organ-specific recommendations do not provide complete medication doses, induction schedules, monitoring or contraindications. Disease severity, affected organs and bleeding risk require individual assessment; anticoagulation is conditional on the stated safeguards.
  • This House summary is based on the linked focused or condensed recommendation sources; it does not represent the complete original publication.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Behçet’s syndrome — 2025 update — focused recommendation source

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
EULAR
First published
23 March 2026
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Assess disease extent and agree treatment goals
  • Treat mucocutaneous and joint disease
  • Protect vision with immunosuppressive treatment
  • Treat arterial aneurysms promptly
  • Balance thrombosis treatment against bleeding risk
  • Manage gastrointestinal and parenchymal neurological disease
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House